Literature DB >> 9382763

Bacterial lipopeptides constitute efficient novel immunogens and adjuvants in parenteral and oral immunization.

W G Bessler1, W Baier, U vd Esche, P Hoffmann, L Heinevetter, K H Wiesmüller, G Jung.   

Abstract

Synthetic lipopeptide analogues derived from the N-terminus of bacterial lipoprotein constitute potent B-lymphocyte and macrophage/monocyte activators in vitro. In vivo they act as immunoadjuvants in parenteral and oral immunization when administered in combination with antigens. When added to bacterial or viral vaccines, lipopeptides markedly enhance the vaccine effect. After the coupling of lipopeptides to haptens or non immunogenic low molecular mass antigens, a specific antibody response is induced often after only one application of the conjugate. The response can be further enhanced by introducing haplotype specific T helper cell epitopes into the conjugate. Lipopeptide antigen conjugates can also be applied as synthetic vaccines that give protection e.g. against foot-and-mouth-disease. The novel chemically well defined lipopeptides described here can be synthesized in gram amounts with high purity and reproducibility; they are non-toxic and can be stored for long time even at room temperature. For veterinary application, by replacing Freund's adjuvant, side reactions and inflammatory processes are avoided.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9382763

Source DB:  PubMed          Journal:  Behring Inst Mitt        ISSN: 0301-0457


  8 in total

1.  Human antibody response to outer membrane protein G1a, a lipoprotein of Moraxella catarrhalis.

Authors:  Diana G Adlowitz; Sanjay Sethi; Paul Cullen; Ben Adler; Timothy F Murphy
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn.

Authors:  Ofer Levy; Melissa Coughlin; Bruce N Cronstein; Rene M Roy; Avani Desai; Michael R Wessels
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

3.  Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses.

Authors:  Partha Karmakar; Kyunghee Lee; Sourav Sarkar; Katherine A Wall; Steven J Sucheck
Journal:  Bioconjug Chem       Date:  2015-12-09       Impact factor: 4.774

4.  Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.

Authors:  Mehfuz Zaman; Abu-Baker M Abdel-Aal; Yoshio Fujita; Karen S M Phillipps; Michael R Batzloff; Michael F Good; Istvan Toth
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

5.  Strategies for intranasal delivery of vaccines.

Authors:  Mehfuz Zaman; Saranya Chandrudu; Istvan Toth
Journal:  Drug Deliv Transl Res       Date:  2012-07-12       Impact factor: 4.617

Review 6.  Novel adjuvants & delivery vehicles for vaccines development: a road ahead.

Authors:  Teena Mohan; Priyanka Verma; D Nageswara Rao
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

7.  A purified recombinant lipopeptide as adjuvant for cancer immunotherapy.

Authors:  Ying-Chyi Song; Hsueh-Hung Liu; I-Hua Chen; Hsin-Wei Chen; Pele Chong; Chih-Hsiang Leng; Shih-Jen Liu
Journal:  Biomed Res Int       Date:  2014-03-11       Impact factor: 3.411

Review 8.  Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants.

Authors:  Kuang Tan; Ruizhen Li; Xiaotian Huang; Qiong Liu
Journal:  Front Microbiol       Date:  2018-04-26       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.